Analyst firms · Barclays · MCK
Barclays MCK price target and rating history
McKesson Corporation (MCK) · Health Care
Barclays rates McKesson Corporation (MCK) Overweight with a $960 price target, as of its latest action on Dec 9, 2025. It has published 4 rating actions on MCK since November 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Overweight
- Price target
- $960
- Median target, all firms
- Too few
- Actions on MCK
- 4
Barclays price target on MCK
Every Barclays rating on MCK
- Dec 9, 2025
- Jan 3, 2024
- Dec 9, 2021
- Nov 2, 2021
How other firms rate MCK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| RBC Capital Markets | Sector Perform | $845 | Aug 19, 2026 |
| William Blair | Outperform | Apr 28, 2026 | |
| Barclays | Overweight | $960 | Dec 9, 2025 |
Questions about Barclays and MCK
- What is Barclays's price target for MCK?
- Barclays's latest stated price target for McKesson Corporation (MCK) is $960, from its action on Dec 9, 2025.
- What is Barclays's rating on MCK?
- Barclays rates MCK Overweight, a bullish rating, as of Dec 9, 2025.
- When did Barclays last change its view on MCK?
- On Dec 9, 2025, Barclays starts coverage at Overweight, price target $960.
More MCK rating histories
All Barclays ratingsMCK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.